ABT — Abbott Laboratories

Summary of Abbott Laboratories Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Adjusted Earnings Per Share (EPS): $1.15, consistent with guidance.
• Sales Growth: 3.7% on a comparable basis, with notable segments:
  • Diagnostics: 2% growth; Core Lab Diagnostics up 3%, but Rapid and Molecular Diagnostics down 10%.
  • Nutrition: Slightly ahead of expectations, transitioning towards volume growth.
  • Established Pharmaceutical Division (EPD): 9% growth, driven by strong performance in Latin America and Asia Pacific.
  • Medical Devices: 8.5% growth, led by cardiovascular devices.
• Gross Margin: Adjusted gross margin at 56.3%.
• Foreign Exchange Impact: Favorable 4% impact on sales year-over-year.

2. Strategic Updates and Business Highlights:

• Acquisition of Exact Sciences: Completed on March 23, 2026, expected to add approximately $3 billion in sales for 2026 and enhance Abbott's diagnostics portfolio.
• Pipeline Achievements: Early approval and launch of new PFA catheters, completion of patient enrollment in key trials, and positive results from diabetes-related studies.
• Product Launches: Focus on new technologies in medical devices, including a balloon-expandable TAVR valve and a wearable lactate monitoring sensor.

3. Forward Guidance and Outlook:

• Full-Year Sales Growth Outlook: Revised to 6.5% to 7.5% on a comparable basis, incorporating Exact Sciences.
• Adjusted EPS Guidance for Q2: Expected in the range of $1.25 to $1.31.
• Growth Acceleration: Confidence in achieving higher growth in the second half of the year, driven by strategic initiatives in Nutrition, Core Lab Diagnostics, and Electrophysiology.

4. Challenges and Points of Concern:

• Weak Respiratory Season Impact: Lower-than-expected demand for respiratory virus testing affected sales in the Rapid and Molecular Diagnostics segment.
• Nutrition Business Transition: Ongoing challenges in balancing price and volume growth; early signs of recovery but still in transition.
• Competitive Pressures: Increased competition in the Structural Heart space and challenges in executing growth in certain markets.
• Market Dynamics in China: Facing headwinds from value-based pricing (VBP) policies, although signs of stabilization are emerging.

5. Notable Q&A Insights:

• Guidance Philosophy: Management emphasized a conservative approach to guidance, factoring in potential risks and uncertainties, particularly regarding respiratory season performance.
• Continuous Glucose Monitoring (CGM) Market: Management remains bullish on CGM growth potential despite current prescription trends, citing significant under-penetration and upcoming reimbursement changes.
• Exact Sciences Integration: Positive outlook on sustaining Cologuard growth, with plans for international expansion and addressing the demand for cancer screening.
• Structural Heart and Electrophysiology: Noted competitive intensity but expressed confidence in product launches and overall market growth potential.

Overall, Abbott Laboratories reported solid financial results in Q1 2026, with strategic initiatives aimed at enhancing growth and addressing challenges across various segments. The integration of Exact Sciences is expected to play a crucial role in future performance, while management remains focused on navigating competitive pressures and market dynamics.